Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cannabidiol (CBD) For Breast Cancer Primary Tumors
NCT06148038Phase 1Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Sep 2026
- Primary completion
- Aug 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in breast cancer comparing CBD Oral with Placebo control (2 arms). Primary endpoints: CBD and cell proliferation at 2 months and CBD and apoptosis at 2 months. Started Sep 2026; status: recruiting.
02
Drugs
cannabidiol
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06148038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06148038.